Beryl Drugs — 360° view

Beryl Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹6.93 crore and net profit of ₹0.06 crore for the September 2026 quarter.

Beryl Drugs (BSE: BERLDRG) closed at ₹24.70 on 20 Nov 2026, up 8.6% over the past year. Its market capitalisation is ₹13 crore and it trades at 18.7 times earnings.

Share price
₹24.70 (20 Nov 2026)
Market cap
₹13 Cr (20 Nov 2026)
P/E
18.69 (20 Nov 2026)
Revenue
₹7 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
7.25% (FY26)
ROE
4.34% (FY26)
Book value
₹20.0 (FY26)
Dividend yield
-0.00% (FY26)
52-week high / low
₹29.90 / ₹15.92 (20 Nov 2026)
1-year return
8.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: BERLDRG

Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.